Details for New Drug Application (NDA): 202933
✉ Email this page to a colleague
NDA 202933 describes AMLODIPINE AND OLMESARTAN MEDOXOMIL, which is a drug marketed by Accord Hlthcare Inc, Ajanta Pharma Ltd, Alembic, Alkem Labs Ltd, Aurobindo Pharma, Glenmark Pharms Ltd, Jubilant Generics, Macleods Pharms Ltd, Micro Labs, Sciegen Pharms Inc, Teva Pharms Usa, Torrent, and Zydus Pharms, and is included in thirteen NDAs. It is available from fifteen suppliers. Additional details are available on the AMLODIPINE AND OLMESARTAN MEDOXOMIL profile page.
The generic ingredient in AMLODIPINE AND OLMESARTAN MEDOXOMIL is amlodipine besylate; olmesartan medoxomil. There are fifty drug master file entries for this compound. Eighteen suppliers are listed for this compound. Additional details are available on the amlodipine besylate; olmesartan medoxomil profile page.
The generic ingredient in AMLODIPINE AND OLMESARTAN MEDOXOMIL is amlodipine besylate; olmesartan medoxomil. There are fifty drug master file entries for this compound. Eighteen suppliers are listed for this compound. Additional details are available on the amlodipine besylate; olmesartan medoxomil profile page.
Summary for 202933
| Tradename: | AMLODIPINE AND OLMESARTAN MEDOXOMIL |
| Applicant: | Torrent |
| Ingredient: | amlodipine besylate; olmesartan medoxomil |
| Patents: | 0 |
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | EQ 5MG BASE;20MG | ||||
| Approval Date: | Nov 25, 2016 | TE: | RLD: | No | |||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | EQ 5MG BASE;40MG | ||||
| Approval Date: | Nov 25, 2016 | TE: | RLD: | No | |||||
Profile for product number 003
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | EQ 10MG BASE;20MG | ||||
| Approval Date: | Nov 25, 2016 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
